BPC 157: Experimental Peptide Creates Risk for Athletes Injectable Peptides: Out of the Back Alley and Into the Light? Berkley Lifesciences FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 Banned: Key Facts on the Latest FDA Decision